Betrnet Stem Cells and the Origins of Barrett's Esophagus Project 3 RF Ablation

NCT01568723 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 125

Last updated 2021-12-15

No results posted yet for this study

Summary

The purpose of this study is to determine biomarkers which can predict response to ablation therapy in patients with Barretts esophagus.

Conditions

  • Barrett's Esophagus

Interventions

GENETIC

response to therapy

evaluate specific markers for response to therapy at specific intervals pre and post therapy

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH
  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Kenneth K Wang, MD · Mayo Clinic

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2018-08-16
Completion
2018-08-16

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01568723 on ClinicalTrials.gov